» Articles » PMID: 38459027

Structural Basis for Self-discrimination by Neoantigen-specific TCRs

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Mar 8
PMID 38459027
Authors
Affiliations
Soon will be listed here.
Abstract

T cell receptors (TCR) are pivotal in mediating tumour cell cytolysis via recognition of mutation-derived tumour neoantigens (neoAgs) presented by major histocompatibility class-I (MHC-I). Understanding the factors governing the emergence of neoAg from somatic mutations is a major focus of current research. However, the structural and cellular determinants controlling TCR recognition of neoAgs remain poorly understood. This study describes the multi-level analysis of a model neoAg from the B16F10 murine melanoma, H2-D/Hsf2 p.K72N, as well as its cognate TCR 47BE7. Through cellular, molecular and structural studies we demonstrate that the p.K72N mutation enhances H2-D binding, thereby improving cell surface presentation and stabilizing the TCR 47BE7 epitope. Furthermore, TCR 47BE7 exhibited high functional avidity and selectivity, attributable to a broad, stringent, binding interface enabling recognition of native B16F10 despite low antigen density. Our findings provide insight into the generation of anchor-residue modified neoAg, and emphasize the value of molecular and structural investigations of neoAg in diverse MHC-I contexts for advancing the understanding of neoAg immunogenicity.

Citing Articles

Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.


Focusing on CD8 T-cell phenotypes: improving solid tumor therapy.

Yao Z, Zeng Y, Liu C, Jin H, Wang H, Zhang Y J Exp Clin Cancer Res. 2024; 43(1):266.

PMID: 39342365 PMC: 11437975. DOI: 10.1186/s13046-024-03195-5.


Strengths and limitations of web servers for the modeling of TCRpMHC complexes.

Le H, de Freitas M, Antunes D Comput Struct Biotechnol J. 2024; 23:2938-2948.

PMID: 39104710 PMC: 11298609. DOI: 10.1016/j.csbj.2024.06.028.


Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

Ascierto P, Agarwala S, Betof Warner A, Ernstoff M, Fox B, Gajewski T J Transl Med. 2023; 21(1):508.

PMID: 37507765 PMC: 10375730. DOI: 10.1186/s12967-023-04325-x.

References
1.
Bellone M, Cantarella D, Castiglioni P, Crosti M, Ronchetti A, Moro M . Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol. 2000; 165(5):2651-6. DOI: 10.4049/jimmunol.165.5.2651. View

2.
Wells D, van Buuren M, Dang K, Hubbard-Lucey V, Sheehan K, Campbell K . Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell. 2020; 183(3):818-834.e13. PMC: 7652061. DOI: 10.1016/j.cell.2020.09.015. View

3.
Bolotin D, Poslavsky S, Mitrophanov I, Shugay M, Mamedov I, Putintseva E . MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015; 12(5):380-1. DOI: 10.1038/nmeth.3364. View

4.
Corse E, Gottschalk R, Krogsgaard M, Allison J . Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 2010; 8(9). PMC: 2939023. DOI: 10.1371/journal.pbio.1000481. View

5.
Baharom F, Ramirez-Valdez R, Tobin K, Yamane H, Dutertre C, Khalilnezhad A . Intravenous nanoparticle vaccination generates stem-like TCF1 neoantigen-specific CD8 T cells. Nat Immunol. 2020; 22(1):41-52. PMC: 7746638. DOI: 10.1038/s41590-020-00810-3. View